These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 31008945)

  • 21. The clinicopathological and prognostic value of programmed death-ligand 1 in colorectal cancer: a meta-analysis.
    Ni X; Sun X; Wang D; Chen Y; Zhang Y; Li W; Wang L; Suo J
    Clin Transl Oncol; 2019 May; 21(5):674-686. PubMed ID: 30392153
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The prevalence and prognostic and clinicopathological value of PD-L1 and PD-L2 in renal cell carcinoma patients: a systematic review and meta-analysis involving 3,389 patients.
    Lu Y; Song Y; Xu Y; Ou N; Liang Z; Hu R; Zhang W; Kang J; Wang X; Liu L; Yang Y; Liu X
    Transl Androl Urol; 2020 Apr; 9(2):367-381. PubMed ID: 32420142
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic Value of PD-L1 in Breast Cancer: A Meta-Analysis.
    Wang C; Zhu H; Zhou Y; Mao F; Lin Y; Pan B; Zhang X; Xu Q; Huang X; Sun Q
    Breast J; 2017 Jul; 23(4):436-443. PubMed ID: 28079291
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PD-1 and PD-L1 expression in HNSCC primary cancer and related lymph node metastasis - impact on clinical outcome.
    Schneider S; Kadletz L; Wiebringhaus R; Kenner L; Selzer E; Füreder T; Rajky O; Berghoff AS; Preusser M; Heiduschka G
    Histopathology; 2018 Oct; 73(4):573-584. PubMed ID: 29742291
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic role of different PD-L1 expression patterns and tumor-infiltrating lymphocytes in high-grade serous ovarian cancer: a systematic review and meta-analysis.
    Wang YM; Cai W; Xue QM; Zhang JY; Zhou L; Xiong SY; Deng H
    Front Immunol; 2023; 14():1234894. PubMed ID: 37654479
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
    Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
    Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value.
    Kim A; Lee SJ; Kim YK; Park WY; Park DY; Kim JY; Lee CH; Gong G; Huh GY; Choi KU
    Sci Rep; 2017 Sep; 7(1):11671. PubMed ID: 28916815
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PD-L1 expression in anogenital and oropharyngeal squamous cell carcinomas associated with different clinicopathological features, HPV status and prognosis: a meta-analysis.
    Qin Y; Luan J; Zhou X; Li Y
    Biosci Rep; 2021 Mar; 41(3):. PubMed ID: 33704390
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of PD-L1 and prognosis in breast cancer: a meta-analysis.
    Zhang M; Sun H; Zhao S; Wang Y; Pu H; Wang Y; Zhang Q
    Oncotarget; 2017 May; 8(19):31347-31354. PubMed ID: 28430626
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis.
    Gao ZH; Li CX; Liu M; Jiang JY
    BMC Cancer; 2020 Nov; 20(1):1150. PubMed ID: 33238978
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors Modifying the Associations of Single or Combination Programmed Cell Death 1 and Programmed Cell Death Ligand 1 Inhibitor Therapies With Survival Outcomes in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-analysis.
    Sati N; Boyne DJ; Cheung WY; Cash SB; Arora P
    JAMA Netw Open; 2021 Jan; 4(1):e2034201. PubMed ID: 33496794
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PD-L1 Acts as a Promising Immune Marker to Predict the Response to Neoadjuvant Chemotherapy in Breast Cancer Patients.
    Du Q; Che J; Jiang X; Li L; Luo X; Li Q
    Clin Breast Cancer; 2020 Feb; 20(1):e99-e111. PubMed ID: 31521537
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High PD-L1 expression in the tumour cells did not correlate with poor prognosis of patients suffering for oral squamous cells carcinoma: A meta-analysis of the literature.
    Troiano G; Caponio VCA; Zhurakivska K; Arena C; Pannone G; Mascitti M; Santarelli A; Lo Muzio L
    Cell Prolif; 2019 Mar; 52(2):e12537. PubMed ID: 30443950
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinicopathological and prognostic values of PD-L1 expression in oesophageal squamous cell carcinoma: a meta-analysis of 31 studies with 5368 patients.
    Liu Z; Sun L; Cai L; Guo M; Xu G; Liu S; Zheng G; Wang Q; Lian X; Feng F; Zhang H
    Postgrad Med J; 2022 Dec; 98(1166):948-957. PubMed ID: 34253568
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic significance of programmed cell death ligand 1 expression in patients with ovarian carcinoma: A systematic review and meta-analysis.
    Huang LJ; Deng XF; Chang F; Wu XL; Wu Y; Diao QZ
    Medicine (Baltimore); 2018 Oct; 97(43):e12858. PubMed ID: 30412078
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
    Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S
    Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: a meta-analysis of 10 studies with 1,901 patients.
    Zhang M; Dong Y; Liu H; Wang Y; Zhao S; Xuan Q; Wang Y; Zhang Q
    Sci Rep; 2016 Nov; 6():37933. PubMed ID: 27892511
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene.
    Li Y; Opyrchal M; Yao S; Peng X; Yan L; Jabbour H; Khoury T
    Breast Cancer Res Treat; 2018 Jul; 170(2):293-302. PubMed ID: 29524062
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic effect of programmed death-ligand 1 (PD-L1) in ovarian cancer: a systematic review, meta-analysis and bioinformatics study.
    Wang L
    J Ovarian Res; 2019 Apr; 12(1):37. PubMed ID: 31039792
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic role of PD-L1 expression in patients with salivary gland carcinoma: A systematic review and meta-analysis.
    Wu L; Jiang C; Zhu Z; Sun Y; Zhang T
    PLoS One; 2022; 17(7):e0272080. PubMed ID: 35881656
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.